Walleye Capital’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-15,399
| Closed | -$223K | – | 4874 |
|
|
2026
Q1 | $223K | Sell |
15,399
-10,631
| -41% | -$152K | ﹤0.01% | 3275 |
|
|
2025
Q4 | $371K | Sell |
26,030
-480,831
| -95% | -$4.72M | ﹤0.01% | 3145 |
|
|
2025
Q3 | $3.99M | Buy |
506,861
+470,443
| +1,292% | +$3.35M | 0.02% | 1074 |
|
|
2025
Q2 | $209K | Buy |
+36,418
| New | +$235K | ﹤0.01% | 3338 |
|
|
2025
Q1 | – | Sell |
-44,516
| Closed | -$419K | – | 4523 |
|
|
2024
Q4 | $419K | Sell |
44,516
-359,725
| -89% | -$3.74M | ﹤0.01% | 3136 |
|
|
2024
Q3 | $4.32M | Buy |
404,241
+392,630
| +3,382% | +$4.28M | 0.01% | 1281 |
|
|
2024
Q2 | $115K | Sell |
11,611
-10,733
| -48% | -$110K | ﹤0.01% | 4648 |
|
|
2024
Q1 | $263K | Buy |
+22,344
| New | +$286K | ﹤0.01% | 3769 |
|
|
2023
Q4 | – | Sell |
-172,169
| Closed | -$2.09M | – | 5133 |
|
|
2023
Q3 | $2.09M | Buy |
+172,169
| New | +$2.22M | 0.01% | 1703 |
|
|
2022
Q1 | – | Sell |
-14,051
| Closed | -$162K | – | 2380 |
|
|
2021
Q4 | $162K | Buy |
+14,051
| New | +$157K | 0.01% | 1541 |
|
|
2021
Q2 | – | Sell |
-33,600
| Closed | -$332K | – | 1397 |
|
|
2021
Q1 | $332K | Buy |
+33,600
| New | +$520K | 0.02% | 718 |
|
|
2019
Q2 | – | Sell |
-414
| Closed | -$5.25K | – | 1839 |
|
|
2019
Q1 | $6K | Buy |
+414
| New | +$5.06K | ﹤0.01% | 1433 |
|
Other funds holding FOLD
Walleye Capital's FOLD Position: Q2 2026 in Review
Walleye Capital sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 15,399 shares — an estimated $223K sold.
Walleye Capital first reported a position in FOLD in Q1 2019 and held it in 12 quarters. The position peaked at $4.32M in Q3 2024. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Walleye Capital reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Walleye Capital sold 15,399 Amicus Therapeutics shares in Q2 2026, an estimated $223K.
- Walleye Capital first reported a position in Amicus Therapeutics in Q1 2019 and held it in 12 quarters.
- Walleye Capital's Amicus Therapeutics position peaked at $4.32M in Q3 2024.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.